Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers

Journal of Clinical Pathology

Volumn 62, Issue 10, 2009, Pages 926-930

  Van Der Groep, Petra ^a   Van Diest, P J ^a   Menko, F H ^b   Bart, J ^c   De Vries, E G E ^c   Van Der Wall, E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GERM LINE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTRADUCTAL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; IMMUNOPHENOTYPING; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 70349696551     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.065524     Document Type: Article

References (53)

1. Claus EB, Schildkraut JM, Thompson WD, et al. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:2318-2324 (Pubitemid 26162426)
2. Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet 1994;343:692-695
3. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi jews. N Engl J Med 1997;336:1401-1408 (Pubitemid 27208598)
4. Zweemer RP, Verheijen RHM, Gille JJP, et al. Clinical and genetic evaluation of 30 ovarian cancer families. Am J Obstet Gynecol 1998;178:85-90. (Pubitemid 28302800)
5. Zweemer RP, van Diest PJ, Verheijen RH, et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 2000;76:45-50.
6. Jonsson G, Naylor TL, Vallon-Christersson J, et al. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res 2005;65:7612-7621
7. van Beers EH, van Welsem T, Wessels LFA, et al. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res 2005;65:822-827
8. Tirkkonen M, Johannsson O, Agnarsson BA, et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997;57:1222-1227 (Pubitemid 27152540)
9. Alvarez S, Diaz-Uriarte R, Osorio A, et al. A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation. Clin Cancer Res 2005;11:1146-1153 (Pubitemid 40175764)
10. Hedenfalk I, Ringner M, Ben-Dor A, et al. Molecular classification of familial non- BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci U S A 2003;100:2532-2537
11. Wessels LF, van Welsem T, Hart AA, et al. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 2002;62:7110-7117
12. Armes JE, Venter DJ. The pathology of inherited breast cancer. Pathology 2002;34:309-314
13. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-2318 (Pubitemid 34441658)
14. Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996;77:697-709. (Pubitemid 26055395)
15. Eisinger F, Stoppa-Lyonnet D, Longy M, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996;56:471-474
16. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997;349:1505-1510
17. Chappuis PO, Nethercot V, Foulkes WD. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 2000;18:287-295 (Pubitemid 30253021)
18. Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implication of the basal-like (Cyclin Ehigh/P27low/p53+/glomeruloid-microvascular- proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004;64:830-835
19. Chappuis PO, Kapusta L, Be'gin LR, et al. Germline BRCA1/2 mutations and p27(Kip1)protein levels independently predict outcome after breast cancer. J Clin Oncol 2000;18:4045-4052 (Pubitemid 32038396)
20. Greenblatt MS, Chappuis PO, Bond JP, et al. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res 2001;61:4092-4097
21. Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-8423 (Pubitemid 36842560)
22. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003;95:1482-1485
23. Eerola H, Heinonen M, Heikkilä P, et al. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation negative breast cancer families. Breast Cancer Res 2008;10:R17.
24. Van der Groep P, Bouter A, van der Zanden R, et al. Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2004;96:712-713
25. Van der Groep P, Bouter A, van der Zanden R, et al. Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J Clin Pathol 2006;59:611-617 (Pubitemid 43886045)
26. Lakhani SR, Reis-Filho JS, Fulford L, et al. Breast Cancer Linkage Consortium. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:5175-5180
27. Van der Groep P, Bouter A, Menko FH, et al. High frequency of HIF-1α overexpression in BRCA1 related breast cancer. Breast Cancer Res Treat 2008;111:475-480
28. Arnes JB, Brunet JS, Stefansson I, et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 2005;11:4003-4011 (Pubitemid 40791563)
29. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998 5;90:1138-1145 (Pubitemid 28380718)
30. Palacios J, Honrado E, Osorio A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 2003;9:3606-3614 (Pubitemid 37169224)
31. Lynch BJ, Holden JA, Buys SS, et al. Pathobiologic characteristics of hereditary breast cancer. Hum Pathol 1998;29:1140-1144 (Pubitemid 28467537)
32. Agnarsson BA, Jonasson JG, Bjornsdottir IB, et al. Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat 1998;47:121-127 (Pubitemid 28046083)
33. Bane AL, Beck JC, Bleiweiss I, et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 2007;31:121-128 (Pubitemid 46036911)
34. Van Diest PJ. Ductal carcinoma in situ in breast carcinogenesis. J Pathol 1999;187:383-384 (Pubitemid 29118267)
35. Mommers ECM, Leonhart AM, Falix F, et al. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. J Pathol 2001;194:327-333 (Pubitemid 32624559)
36. Castro NP, Osório CA, Torres C, et al. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res 2008;10:R87.
37. Claus EB, Petruzella S, Matloff E, et al. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 2005;293:964-969 (Pubitemid 40271128)
38. Hwang ES, McLennan JL, Moore DH, et al. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol 2007;25:642-647 (Pubitemid 350002918)
39. Kauff ND, Brogi E, Scheuer L, et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 2003;97:1601-1608 (Pubitemid 36350702)
40. Hoogerbrugge N, Bult P, Bonenkamp JJ, et al. Numerous high-risk epithelial lesions in familial breast cancer. Eur J Cancer 2006;42:2492-2498 (Pubitemid 44442941)
41. Kroiss R, Winkler V, Kalteis K, et al. The Austrian Hereditary Breast and Ovarian Cancer Group. Prevalence of pre-malignant and malignant lesions in prophylactic mastectomy specimens of BRCA1 mutation carriers: comparison with a control group. J Cancer Res Clin Oncol 2008;134:1113-1121
42. Hermsen BB, van Diest PJ, Berkhof J, et al. Low prevalence of (pre)malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer. Int J Cancer 2006;119:1412-1418 (Pubitemid 44258819)
43. Hoogerbrugge N, Bult P, de Widt-Levert LM, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 2003;21:41-45
44. Smith KL, Adank M, Kauff N, et al. BRCA mutations in women with ductal carcinoma in situ. Clin Cancer Res 2007;13:4306-4310
45. Arun B, Vogel KJ, Lopez A, et al. High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res (Phila Pa) 2009;2:122-127
46. Farabegoli F, Champeme MH, Bieche I, et al. Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol 2002;196:280-286 (Pubitemid 34189416)
47. Hermsen BBJ, Von Mensdorff-Pouilly S, Fabry HFJ, et al. Lobulitis is a frequent finding in prophylactically removed breast tissue from women at hereditary high risk of breast cancer. J Pathol 2005;206:220-223
48. Van Diest PJ. No consent should be needed for using leftover body material for scientific purposes. BMJ 2002;325:648-651
49. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994;11:167-180 (Pubitemid 24308077)
50. Tamimi RM, Baer HJ, Marotti J, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008;10:R67.
51. Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 1999;96:9212-9217 (Pubitemid 29374734)
52. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874 (Pubitemid 32878711)
53. Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005 10;23:7350-7360